Bucindolol: a pharmacogenomic perspective on its use in chronic heart failure.

13 The latter fact suggests some increase in myocardial efficiency, although comparisons did not reach statistical significance in the trial by Eichhorn and colleagues. 13 The improved ventricular performance may be predominantly due to the enhanced cardiac contractility and not due to the modest vasodilator effect. 13 This improvement in contractility has been confirmed by relatively load-independent methods (end-systolic

also in 111,027 other papers

73 It should be noted that, in the BEST trial, a nominally significant interaction effect of therapy was found only for race (African American vs.

also in 7,732 other papers